Identifying new treatments for opioid use disorders using DNA technology
The use of DNA-encoded library (DEL) technology for the identification of therapeutic molecules to treat opioid use disorders (OUDs)
This study is looking for new treatments for people dealing with opioid use disorders by finding special molecules that can help balance brain function without directly affecting opioid receptors, which could lead to safer and more effective options for recovery.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Jillion Therapeutics INC. NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11005426 on NIH RePORTER |
What this research studies
This research focuses on discovering new therapeutic molecules to treat opioid use disorders (OUDs) by utilizing a cutting-edge DNA-encoded library (DEL) technology. The approach aims to identify small compounds that can bind to a specific receptor in the brain, GPR26, which is involved in the reward system, without affecting the opioid receptors directly. By targeting these orphan G-protein coupled receptors, the research seeks to restore normal brain function disrupted by opioid dependency. This innovative method could lead to safer and more effective treatments for individuals struggling with OUDs.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are experiencing opioid use disorders.
Not a fit: Patients who are not struggling with opioid use disorders or those who are under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new, non-opioid treatments that help individuals recover from opioid use disorders.
How similar studies have performed: While the approach of targeting orphan GPCRs is innovative, similar research has shown promise in exploring alternative pathways for treating substance use disorders.
Where this research is happening
New York, United States
- Jillion Therapeutics INC. — New York, United States (Active)
Researchers
- Principal investigator: Flajolet, Marc — Jillion Therapeutics INC.
- Study coordinator: Flajolet, Marc
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.